search
Back to results

Memantine for Post-Operative Pain Control

Primary Purpose

Pain, Post-operative

Status
Unknown status
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Memantine
Placebo
Sponsored by
University of Washington
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Post-operative focused on measuring Adjuvants, pharmaceuticals, Receptors, N-Methyl-D-Aspartate, Drug tolerance, Pain Measurement

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Surgery for total hip replacement, knee replacement OR lumbar spinal fusion
  • Taking no opiate medication OR taking opiate medication for at least 6 weeks

Exclusion Criteria:

  • History of alcohol or drug abuse
  • Clinical diagnosis of Alzheimer's Disease
  • Prior adverse reaction to memantine
  • Severe renal impairment (creatinine clearance <30 ml/min)
  • Inability to give informed consent

Sites / Locations

  • University of Washington Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Opiate Naive

Opiate tolerant

Arm Description

Subjects who have not taken opiate medication in previous 6 weeks before surgery

Subjects who have taken opiate medications for the 6 weeks before surgery

Outcomes

Primary Outcome Measures

Change in numerical ratings on pain diaries as outpatients (pre and post surgery)
Daily pain numerical ratings at rest and with movement as inpatients.
Total opiate dose via patient controlled IV hydromorphone
Oxycodone dose taken prn

Secondary Outcome Measures

Treatment group differences in side effects (nausea, itching, sedation, urinary retention following foley catheter discontinuation)
Changes in cognitive function, assessed with Digit-Symbol Substitution Test and Trail Making Test B
Changes in pain and quality of life questionnaire responses (SF-McGill-2, Brief Pain Questionnaire, SF-36 v2)

Full Information

First Posted
December 29, 2009
Last Updated
June 25, 2010
Sponsor
University of Washington
Collaborators
Forest Laboratories
search

1. Study Identification

Unique Protocol Identification Number
NCT01041313
Brief Title
Memantine for Post-Operative Pain Control
Official Title
Memantine for Post-Operative Pain Control
Study Type
Interventional

2. Study Status

Record Verification Date
June 2010
Overall Recruitment Status
Unknown status
Study Start Date
January 2010 (undefined)
Primary Completion Date
June 2011 (Anticipated)
Study Completion Date
September 2011 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
University of Washington
Collaborators
Forest Laboratories

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Pain is a common element of surgery. Opiates (morphine, oxycodone, hydrocodone, methadone, fentanyl) are very helpful in decreasing pain after surgery. Unfortunately, with repeated use opiates lose their effectiveness, such that patients need to utilize more opiates to achieve adequate pain relief - a phenomenon called tolerance. Sometimes tolerance to a pain reliever's effects can develop in just a few hours. It is thought that activation of the N-methyl d-aspartate (NMDA) receptor, a "switch" found on the surface of nerves, is partially responsible for opiate tolerance. Memantine is a medication that limits the activity of NMDA receptors in the brain and spinal cord. It has been used for years to help patients with Alzheimer's Disease. In this study, we will study the effects of memantine when combined with opiate medications to see whether it can increase the effectiveness of opiates for pain after surgery and reduce the side effects caused by opiates (e.g., sedation, nausea, itching).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Post-operative
Keywords
Adjuvants, pharmaceuticals, Receptors, N-Methyl-D-Aspartate, Drug tolerance, Pain Measurement

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Opiate Naive
Arm Type
Active Comparator
Arm Description
Subjects who have not taken opiate medication in previous 6 weeks before surgery
Arm Title
Opiate tolerant
Arm Type
Active Comparator
Arm Description
Subjects who have taken opiate medications for the 6 weeks before surgery
Intervention Type
Drug
Intervention Name(s)
Memantine
Other Intervention Name(s)
Namenda
Intervention Description
7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
Primary Outcome Measure Information:
Title
Change in numerical ratings on pain diaries as outpatients (pre and post surgery)
Time Frame
For 1 week pre-surgery, through 2 weeks post-surgery
Title
Daily pain numerical ratings at rest and with movement as inpatients.
Time Frame
Immediately post-surgery until discharge (2-3 days)
Title
Total opiate dose via patient controlled IV hydromorphone
Time Frame
Post-surgery day 1
Title
Oxycodone dose taken prn
Time Frame
Post-surgery day 2 through 3 months.
Secondary Outcome Measure Information:
Title
Treatment group differences in side effects (nausea, itching, sedation, urinary retention following foley catheter discontinuation)
Time Frame
One week pre-surgery through 3 months post-surgery
Title
Changes in cognitive function, assessed with Digit-Symbol Substitution Test and Trail Making Test B
Time Frame
One week pre-surgery, immediately pre-surgery, and post-surgery days 1, 2, 3
Title
Changes in pain and quality of life questionnaire responses (SF-McGill-2, Brief Pain Questionnaire, SF-36 v2)
Time Frame
One week pre-surgery through 3 months post-surgery, particularly as outpatient

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Surgery for total hip replacement, knee replacement OR lumbar spinal fusion Taking no opiate medication OR taking opiate medication for at least 6 weeks Exclusion Criteria: History of alcohol or drug abuse Clinical diagnosis of Alzheimer's Disease Prior adverse reaction to memantine Severe renal impairment (creatinine clearance <30 ml/min) Inability to give informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lydia Stout, BA
Phone
206-914-9253
Email
lstout@uw.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gregory Terman, MD, PhD
Organizational Affiliation
University of Washington Department of Anesthesiology and Pain Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Washington Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lydia Stout, BA
Phone
206-914-9253
Email
lstout@uw.edu

12. IPD Sharing Statement

Citations:
PubMed Identifier
18806055
Citation
Grande LA, O'Donnell BR, Fitzgibbon DR, Terman GW. Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient. Anesth Analg. 2008 Oct;107(4):1380-3. doi: 10.1213/ane.0b013e3181733ddd.
Results Reference
background

Learn more about this trial

Memantine for Post-Operative Pain Control

We'll reach out to this number within 24 hrs